Influences of apatinib combined with thymosin α1 on the curative effect in patients with primary hepatic carcinoma after TACE
Objective:To observe the influences of apatinib combined with thymosin α1 on the curative effect in patients with primary hepatic carcinoma(PHC)after transcatheter arterial chemoembolization(TACE).Methods:A total of 90 patients with PHC admitted to the hospital were enrolled as the research objects between February 2020 and February 2022.According to random number table method,they were divided into observation group and control group,45 cases in each group.After TACE,control group was given subcutaneous injection of thymosin α1 in the morning,while observation group was additionally given oral apatinib after dinner.After treatment,contrast-enhanced CT or MRI of upper abdomen was re-examined.According to enhancement appearances at arterial phase,clinical curative effect in both groups was evaluated.The levels of liver function indexes and serum tumor markers were compared between the two groups before and after treatment.Results:The objective response rate(ORR)and disease control rate(DCR)in observation group were significantly higher than those in control group(P<0.05).After treatment,levels of alanine aminotransferase(ALT),aspartate transaminase(AST),total bilirubin(TBIL),alpha-fetoprotein(AFP),vascular endothelial growth factor(VEGF)and fibroblast growth factor(FGF)were significantly decreased in both groups,which were significantly lower in observation group than control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Apatinib combined with thymosin α1 can effectively improve disease control rate and treatment response rate,reduce levels of serum tumor markers and promote the recovery of liver function in PHC patients after TACE,with high medication safety.
万方数据
维普
